Eli Lilly and Company (LLY) stock analysis

Eli Lilly and Company — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 7.6/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Eli Lilly and Company shows trailing revenue of $72.25B, a 82.8% gross margin, net debt of $31.97B, EPS of 23.92, valued at about 15.0x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $1210.02
• YTD Return: +12.0%
• Revenue TTM: $72.25B
• Revenue Trend: YoY +55.5%
• Gross Margin: 82.8%
• Net Cash: $-31.97B
• EPS: 23.92
• P/S Ratio: 15.0x

Compare: LLY vs UNH · LLY vs JNJ · LLY vs PFE | Also: UNH, JNJ, PFE, MRK, ABBV, TMO